These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 15776028)
1. [Biology and treatment options during the development of prostate cancer]. Lilleby W; Sudbø J; Fosså SD Tidsskr Nor Laegeforen; 2005 Mar; 125(5):571-4. PubMed ID: 15776028 [TBL] [Abstract][Full Text] [Related]
2. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Armstrong AJ; Febbo PG Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Fradet Y Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493 [TBL] [Abstract][Full Text] [Related]
4. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. Vicini FA; Vargas C; Abner A; Kestin L; Horwitz E; Martinez A J Urol; 2005 May; 173(5):1456-62. PubMed ID: 15821460 [TBL] [Abstract][Full Text] [Related]
5. [Markers for diagnosis, prediction and prognosis of prostate cancer]. Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854 [TBL] [Abstract][Full Text] [Related]
6. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use. Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381 [TBL] [Abstract][Full Text] [Related]
7. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629 [TBL] [Abstract][Full Text] [Related]
8. The use of PSA as biomarker in nutritional intervention studies of prostate cancer. van Weerden WM; Schröder FH Chem Biol Interact; 2008 Jan; 171(2):204-11. PubMed ID: 18177847 [TBL] [Abstract][Full Text] [Related]
9. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Bickers B; Aukim-Hastie C Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347 [TBL] [Abstract][Full Text] [Related]
11. Salvage options for biochemical recurrence after primary therapy for prostate cancer. Bong GW; Keane TE Can J Urol; 2007 Dec; 14 Suppl 1():2-9. PubMed ID: 18163938 [TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer. Eastham JA Nat Clin Pract Urol; 2005 Oct; 2(10):482-91. PubMed ID: 16474622 [TBL] [Abstract][Full Text] [Related]
13. New circulating biomarkers for prostate cancer. Bensalah K; Lotan Y; Karam JA; Shariat SF Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918 [TBL] [Abstract][Full Text] [Related]
14. Blood biomarkers for prostate cancer detection and prognosis. Shariat SF; Karam JA; Roehrborn CG Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720 [TBL] [Abstract][Full Text] [Related]
15. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ; J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480 [TBL] [Abstract][Full Text] [Related]
16. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median. Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803 [TBL] [Abstract][Full Text] [Related]
17. Update on outcomes research databases in prostate cancer 2006. Freedland SJ; Krupski TL; Moul JW Curr Opin Urol; 2006 May; 16(3):168-72. PubMed ID: 16679854 [TBL] [Abstract][Full Text] [Related]
18. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis]. Pfitzenmaier J; Altwein JE Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209 [TBL] [Abstract][Full Text] [Related]
19. Biomarkers for prostate cancer detection. Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845 [TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy and the risk of prostate cancer. Is there a link? Barqawi A; Crawford ED Int J Impot Res; 2006; 18(4):323-8. PubMed ID: 16281043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]